EA201491164A1 - Трансдермальная система доставки - Google Patents
Трансдермальная система доставкиInfo
- Publication number
- EA201491164A1 EA201491164A1 EA201491164A EA201491164A EA201491164A1 EA 201491164 A1 EA201491164 A1 EA 201491164A1 EA 201491164 A EA201491164 A EA 201491164A EA 201491164 A EA201491164 A EA 201491164A EA 201491164 A1 EA201491164 A1 EA 201491164A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- buprenorphine
- adhesive
- self
- acid
- mixture
- Prior art date
Links
- 229940100640 transdermal system Drugs 0.000 title 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract 8
- 229960001736 buprenorphine Drugs 0.000 abstract 8
- 239000000853 adhesive Substances 0.000 abstract 5
- 239000012790 adhesive layer Substances 0.000 abstract 3
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 abstract 2
- 150000001735 carboxylic acids Chemical class 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000011241 protective layer Substances 0.000 abstract 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000005642 Oleic acid Substances 0.000 abstract 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 abstract 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 abstract 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract 1
- 239000010410 layer Substances 0.000 abstract 1
- 229940040102 levulinic acid Drugs 0.000 abstract 1
- 229960004488 linolenic acid Drugs 0.000 abstract 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 abstract 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract 1
- 229960002969 oleic acid Drugs 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569609P | 2011-12-12 | 2011-12-12 | |
| PCT/IB2012/002973 WO2013088254A1 (en) | 2011-12-12 | 2012-12-12 | Transdermal delivery system comprising buprenorphine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201491164A1 true EA201491164A1 (ru) | 2014-10-30 |
Family
ID=47754872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491164A EA201491164A1 (ru) | 2011-12-12 | 2012-12-12 | Трансдермальная система доставки |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20140363487A1 (enExample) |
| EP (1) | EP2790685B1 (enExample) |
| JP (2) | JP6289378B2 (enExample) |
| KR (1) | KR102014565B1 (enExample) |
| CN (2) | CN107669662A (enExample) |
| AP (1) | AP4036A (enExample) |
| AR (1) | AR089201A1 (enExample) |
| AU (1) | AU2012327247B2 (enExample) |
| BR (1) | BR112014014137A2 (enExample) |
| CA (1) | CA2858531C (enExample) |
| CL (1) | CL2014001559A1 (enExample) |
| CO (1) | CO7000779A2 (enExample) |
| CR (1) | CR20140321A (enExample) |
| DE (1) | DE112012005185T5 (enExample) |
| EA (1) | EA201491164A1 (enExample) |
| ES (1) | ES2647516T3 (enExample) |
| GB (1) | GB2512007B8 (enExample) |
| IL (1) | IL233025A0 (enExample) |
| MX (1) | MX352795B (enExample) |
| PE (1) | PE20142341A1 (enExample) |
| PH (1) | PH12014501231A1 (enExample) |
| PL (1) | PL2790685T3 (enExample) |
| SG (2) | SG11201403162XA (enExample) |
| TN (1) | TN2014000233A1 (enExample) |
| TW (1) | TW201338813A (enExample) |
| WO (1) | WO2013088254A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| DE102006054731B4 (de) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| EP2729148A4 (en) | 2011-07-06 | 2015-04-22 | Parkinson S Inst | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| WO2013086217A1 (en) | 2011-12-06 | 2013-06-13 | Masco Corporation Of Indiana | Ozone distribution in a faucet |
| AU2012327247B2 (en) | 2011-12-12 | 2015-12-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system |
| WO2013126552A1 (en) | 2012-02-21 | 2013-08-29 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片 |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| DE112014002664T5 (de) * | 2013-06-04 | 2016-04-07 | Lts Lohmann Therapie-Systeme Ag | Transdermales Verabreichungssystem |
| EP3016641B1 (de) | 2013-07-03 | 2018-09-05 | LTS Lohmann Therapie-Systeme AG | Transdermales therapeutisches system mit elektronischem bauteil |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| EP3145502B1 (en) | 2014-05-20 | 2022-07-06 | LTS Lohmann Therapie-Systeme AG | Transdermal delivery system containing rotigotine |
| EP3145503A1 (en) | 2014-05-20 | 2017-03-29 | LTS Lohmann Therapie-Systeme AG | Method for adjusting the release of active agent in a transdermal delivery system |
| EP4238580A3 (en) * | 2014-05-20 | 2023-10-25 | LTS Lohmann Therapie-Systeme AG | Transdermal delivery system including an interface mediator |
| CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| WO2016123406A1 (en) | 2015-01-28 | 2016-08-04 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| CA3104099A1 (en) * | 2015-03-10 | 2016-09-15 | Rhodes Technologies | Acetate salt of buprenorphine and methods for preparing buprenorphine |
| CA2977814A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
| EP3067050A1 (en) | 2015-03-13 | 2016-09-14 | Acino AG | Transdermal therapeutic system with an overtape comprising two adhesive layers |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017048595A1 (en) * | 2015-09-14 | 2017-03-23 | Amneal Pharmaceuticals Llc | Transdermal delivery system |
| CN108463437B (zh) | 2015-12-21 | 2022-07-08 | 德尔塔阀门公司 | 包括消毒装置的流体输送系统 |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| CA3049529A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| WO2019064026A1 (en) | 2017-09-29 | 2019-04-04 | Orexo Ab | NEW PHARMACEUTICAL COMPOSITIONS |
| GB201716830D0 (en) | 2017-10-13 | 2017-11-29 | Cambrex Charles City Inc | New Process |
| CN111971032A (zh) | 2018-03-13 | 2020-11-20 | 罗曼治疗系统股份公司 | 包含有机硅丙烯酸杂化聚合物的透皮治疗系统 |
| WO2019175101A1 (en) | 2018-03-13 | 2019-09-19 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system comprising a silicone acrylic hybrid polymer |
| US20210008000A1 (en) | 2018-03-13 | 2021-01-14 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system comprising a silicone acrylic hybrid polymer |
| AU2019279884B2 (en) | 2018-05-29 | 2025-01-30 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| JP2022507660A (ja) | 2018-11-16 | 2022-01-18 | モーニングサイド ベンチャー インベストメンツ リミテッド | 温度によって調節される経皮薬剤送達システム |
| GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
| CN113952319A (zh) * | 2021-11-30 | 2022-01-21 | 烟台大学 | 一种含丁丙诺啡的骨架型透皮贴剂及其制备方法 |
| CN114397411A (zh) * | 2021-12-14 | 2022-04-26 | 苏州高迈药业有限公司 | 一种评价利丙双卡因乳膏的方法 |
| WO2024040897A1 (zh) * | 2022-08-24 | 2024-02-29 | 新领医药技术(深圳)有限公司 | 沙利度胺或其类似物透皮贴剂及其制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US119585A (en) * | 1871-10-03 | Improvement in horse-collars and hames | ||
| US3474101A (en) | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
| GB1136214A (en) | 1965-06-15 | 1968-12-11 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
| US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
| CA2002299A1 (en) | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
| US5240711A (en) | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
| DE3939376C1 (enExample) | 1989-11-29 | 1991-05-08 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De | |
| US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
| US5635203A (en) * | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
| DE4446600A1 (de) | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen |
| US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| DE19922662C1 (de) | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
| BR0012152A (pt) | 1999-07-02 | 2002-03-12 | Lohmann Therapie Syst Lts | Sistema de microrreservatórios na base de polissiloxanos e solventes ambifìlicos |
| DE19958554C2 (de) | 1999-07-02 | 2002-06-13 | Lohmann Therapie Syst Lts | Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung |
| WO2001014336A1 (en) * | 1999-08-20 | 2001-03-01 | Nippon Kayaku Kabushiki Kaisha | Benzene derivatives substituted by aromatic ring and process for producing the same |
| WO2001058447A1 (en) | 2000-02-08 | 2001-08-16 | Euro-Celtique, S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| JP4659943B2 (ja) * | 2000-02-25 | 2011-03-30 | 帝三製薬株式会社 | 塩酸ブプレノルフィン含有貼付剤 |
| US6844727B2 (en) * | 2000-06-28 | 2005-01-18 | Baker Hughes Incorporated | Method and apparatus of reducing ringing in a nuclear magnetic resonance probe |
| US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
| JP2004525960A (ja) * | 2001-02-16 | 2004-08-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 尿失禁、特に切迫尿失禁の治療用経皮デリバリーディバイスの製造にブプレノルフィンを使用する方法 |
| DE10141651B4 (de) | 2001-08-24 | 2007-02-15 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung |
| US20050118245A1 (en) | 2002-03-27 | 2005-06-02 | Wilsmann Klaus M. | Assembled unit consisting of individually separable, transdermal, therapeutic systems |
| DE10213772A1 (de) | 2002-03-27 | 2003-10-09 | Gruenenthal Gmbh | Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen |
| US20050191340A1 (en) * | 2002-08-09 | 2005-09-01 | Gruenenthal Gmbh | Opioid-receptor antagonists in transdermal systems having buprenorphine |
| AU2003283055A1 (en) * | 2002-08-09 | 2004-02-25 | Grunenthal Gmbh | Opioid-receptor antagonists in transdermal systems having buprenorphine |
| JP5054893B2 (ja) | 2002-12-13 | 2012-10-24 | ユーロ−セルティーク エス．エイ． | 鎮痛のためのブプレノルフィン経皮投与計画 |
| RU2324372C2 (ru) | 2003-03-25 | 2008-05-20 | Моринда, Инк. | Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека |
| US7182955B2 (en) * | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
| US8790689B2 (en) * | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
| DE102004045599A1 (de) | 2004-09-17 | 2006-03-23 | Grünenthal GmbH | System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen |
| DE102004062647A1 (de) | 2004-12-21 | 2006-06-29 | Kronotec Ag | Holzfaserdämmstoffplatte bzw.- matte |
| DE102004062614B4 (de) | 2004-12-24 | 2011-12-29 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung |
| DE102006054732B4 (de) | 2006-11-21 | 2010-12-30 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren |
| DE102006054731B4 (de) * | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
| EP2366388A1 (de) | 2010-03-17 | 2011-09-21 | Ratiopharm GmbH | Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin |
| AU2012327247B2 (en) | 2011-12-12 | 2015-12-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system |
| AU2013205080B2 (en) | 2012-12-12 | 2016-07-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal Delivery System |
| DE112014002664T5 (de) | 2013-06-04 | 2016-04-07 | Lts Lohmann Therapie-Systeme Ag | Transdermales Verabreichungssystem |
-
2012
- 2012-12-12 AU AU2012327247A patent/AU2012327247B2/en not_active Ceased
- 2012-12-12 PE PE2014000948A patent/PE20142341A1/es not_active Application Discontinuation
- 2012-12-12 EA EA201491164A patent/EA201491164A1/ru unknown
- 2012-12-12 ES ES12826670.7T patent/ES2647516T3/es active Active
- 2012-12-12 SG SG11201403162XA patent/SG11201403162XA/en unknown
- 2012-12-12 AP AP2014007779A patent/AP4036A/en active
- 2012-12-12 CN CN201711075001.2A patent/CN107669662A/zh active Pending
- 2012-12-12 DE DE112012005185.8T patent/DE112012005185T5/de not_active Ceased
- 2012-12-12 CN CN201280069476.XA patent/CN104114161A/zh active Pending
- 2012-12-12 JP JP2014546672A patent/JP6289378B2/ja active Active
- 2012-12-12 CA CA2858531A patent/CA2858531C/en active Active
- 2012-12-12 WO PCT/IB2012/002973 patent/WO2013088254A1/en not_active Ceased
- 2012-12-12 AR ARP120104673A patent/AR089201A1/es unknown
- 2012-12-12 GB GB1412385.5A patent/GB2512007B8/en active Active
- 2012-12-12 BR BR112014014137A patent/BR112014014137A2/pt not_active Application Discontinuation
- 2012-12-12 EP EP12826670.7A patent/EP2790685B1/en active Active
- 2012-12-12 SG SG10201604754VA patent/SG10201604754VA/en unknown
- 2012-12-12 TW TW101146918A patent/TW201338813A/zh unknown
- 2012-12-12 KR KR1020147019186A patent/KR102014565B1/ko active Active
- 2012-12-12 MX MX2014007020A patent/MX352795B/es active IP Right Grant
- 2012-12-12 US US14/364,192 patent/US20140363487A1/en not_active Abandoned
- 2012-12-12 PL PL12826670T patent/PL2790685T3/pl unknown
-
2014
- 2014-05-28 TN TNP2014000233A patent/TN2014000233A1/en unknown
- 2014-05-30 PH PH12014501231A patent/PH12014501231A1/en unknown
- 2014-06-08 IL IL233025A patent/IL233025A0/en unknown
- 2014-06-12 CL CL2014001559A patent/CL2014001559A1/es unknown
- 2014-07-04 CR CR20140321A patent/CR20140321A/es unknown
- 2014-07-11 CO CO14149730A patent/CO7000779A2/es unknown
-
2016
- 2016-01-11 US US14/992,122 patent/US9549903B2/en active Active
- 2016-10-07 JP JP2016198650A patent/JP2017036304A/ja active Pending
- 2016-10-10 US US15/289,507 patent/US20170049713A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,920 patent/US20200306204A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491164A1 (ru) | Трансдермальная система доставки | |
| TN2015000493A1 (en) | Transdermal delivery system | |
| EA201591124A1 (ru) | Трансдермальная система доставки | |
| EA201290859A1 (ru) | Лечение люпус-артрита с использованием лаквинимода | |
| MX382195B (es) | Sistema terapeutico transdermico que contiene asenapina | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| MX345344B (es) | Sistema terapéutico transdérmico para la administración de una sustancia activa. | |
| NZ611920A (en) | Percutaneous absorption preparation containing rivastigmine | |
| MX2014002215A (es) | Sistema terapeutico transdermico para clorhidrato de acido 5-aminolevulinico. | |
| UA114101C2 (xx) | Трансдермальна терапевтична система для введення фентанілу або його аналога | |
| EA201590202A1 (ru) | Опиоидные препараты | |
| TN2015000037A1 (en) | Transdermal formulation containing cox inhibitors | |
| MX2015010967A (es) | Formulaciones transdermicas de laquinimod. | |
| RU2012146166A (ru) | Способ профилактики поражения слизистой оболочки желудка при иммобилизации в эксперименте |